AVITA Medical, Inc. (RCEL)
15.62
-0.37
(-2.31%)
USD |
NASDAQ |
Nov 20, 16:00
15.58
-0.04
(-0.26%)
After-Hours: 20:00
AVITA Medical Research and Development Expense (TTM) : 21.10M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 21.10M |
| June 30, 2026 | 20.15M |
| March 31, 2026 | 20.18M |
| December 31, 2025 | 20.84M |
| September 30, 2025 | 20.00M |
| June 30, 2025 | 21.68M |
| March 31, 2025 | 21.45M |
| December 31, 2024 | 20.36M |
| September 30, 2024 | 22.27M |
| June 30, 2024 | 21.24M |
| March 31, 2024 | 21.43M |
| Date | Value |
|---|---|
| December 31, 2023 | 20.82M |
| September 30, 2023 | 17.44M |
| June 30, 2023 | 16.84M |
| March 31, 2023 | 14.82M |
| December 31, 2022 | 13.86M |
| September 30, 2022 | 14.45M |
| June 30, 2022 | 14.76M |
| March 31, 2022 | 15.06M |
| June 30, 2021 | 14.65M |
| March 31, 2021 | 13.01M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Iovance Biotherapeutics, Inc. | 241.88M |
| Halozyme Therapeutics, Inc. | 112.90M |
| Agenus, Inc. | 45.74M |
| Amgen, Inc. | 7.849B |
| Fate Therapeutics, Inc. | 87.29M |